临床试验/NCT03539536

NCT03539536进行中（未招募）2 期

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

AbbVie252 个研究点分布在 2 个国家目标入组 270 人开始时间: 2018年10月10日最近更新: 2025年11月5日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 270
试验地点: 252
主要终点: Number of Participants with Adverse Events (Alternate dose cohort)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Have locally advanced or metastatic non-small cell lung cancer (NSCLC).
•Have c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory. Participant must submit archival or fresh tumor material for assessment of c-Met levels during the prescreening period. Tumor material from the primary tumor site and/or metastatic sites are allowed. If archival tissue is negative for c-Met overexpression, subject can submit fresh biopsy material for reassessment of c-Met expression.
•Histologically documented non-squamous epidermal growth factor receptor (EGFR) wild type NSCLC (site documented EGFR status). Of note, subjects with other actionable mutations are eligible as long as EGFR status is known and all other eligibility criteria are met. As of Protocol Version 11, Stage 1 is complete and Stage 2 is enrolling participants with non-squamous EGFR wild type NSCLC only.
•Must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting.
•Multiple lines of tyrosine kinase inhibitors (TKIs) targeting the same tyrosine kinase (TK) count as 1 line of therapy for the purposes of this eligibility criterion.
•Progressed on systemic cytotoxic therapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible), and prior anticancer therapies targeting driver gene alterations (if applicable).
•Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
•Treatment with any therapies within the noted time intervals is excluded prior to the first dose of telisotuzumab vedotin as noted in the protocol.
•Metastases to the central nervous system (CNS) are eligible only after definitive therapy (such as surgery or radiotherapy) is provided within the protocol.

排除标准

•Have received radiation therapy to the lungs < 6 months prior to the first dose of telisotuzumab vedotin.
•Have received any live vaccine within 30 days of the first dose of investigational product.
•Has adenosquamous histology.
•Have a history of other malignancies except those noted within the protocol.
•Have a history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids.
•Have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD within 3 months of the planned first dose of the study drug (Except for Sites in Ireland). For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor.
•For Sites in Ireland Only: Must not have any evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or ILD. For imaging findings deemed clinically insignificant by the treating physician, subject may be eligible after discussion with and approval from the AbbVie medical monitor.
•Have a clinically significant condition(s) as noted in the protocol.
•Have unresolved clinically significant adverse events of Grade >= 2 from prior anticancer therapy, except for alopecia or anemia.
•Have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin.
•For Sites in France and Czech Republic Only: Have the following:
•Known human immunodeficiency virus (HIV) infection. Note: HIV testing is not required for eligibility for this protocol unless mandated by local regulatory authority or ethics committee/institutional review board.
•Active hepatitis B virus (HBV) infection, defined by hepatitis B surface antigen (HBsAg) positivity or HBV DNA >= 500 IU/mL. In participants with known HBV infection, the presence of active infection must be tested locally. If HBV status is unknown, it must be tested locally at screening.
•Active hepatitis C virus (HCV) infection, defined by HCV ribonucleic acid (RNA) positivity. Participants cured of HCV infection may be included in the study. In participants with known HCV infection, the presence of active infection must be tested locally. If HCV status is unknown, it must be tested locally at screening.
•Uncontrolled autoimmune disease.

研究组 & 干预措施

Telisotuzumab vedotin

Experimental

Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.

干预措施: Telisotuzumab vedotin (Drug)

结局指标

主要结局

Number of Participants with Adverse Events (Alternate dose cohort)

时间窗: Up to approximately 3 years

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Overall Response Rate (ORR) (Stage 1 and Stage 2)

时间窗: Up to approximately 3 years

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

次要结局

Duration of Response (DoR) (Stage 1 and Stage 2)(Up to approximately 3 years)
Overall Survival (OS) (Stage 1 and Stage 2)(Up to approximately 3 years)
Progression-Free Survival (PFS) (Stage 1 and Stage 2)(Up to approximately 3 years)
Disease Control Rate (DCR) (Stage 1 and Stage 2)(Up to approximately 3 years)

研究者

发起方

AbbVie

申办方类型

Industry

责任方

Sponsor

研究点 (252)

Loading locations...

相似试验

终止

2 期

KN046 in Patients With Advanced Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

NCT03838848Jiangsu Alphamab Biopharmaceuticals Co., Ltd120

已完成

2 期

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric CancerGastric Cancer

NCT00952497ACT Biotech, Inc48

招募中

2 期

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer RecurrentNon-small Cell Lung Cancer

NCT06463665Genelux Corporation142

已完成

1 期

Effect of Talactoferrin in Adults With Non-Small Cell Lung CancerNon-Small Cell Lung Cancer

NCT00923741National Cancer Institute (NCI)10

已完成

2 期

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Cancer

NCT00051974Millennium Pharmaceuticals, Inc.155